目的：研究玻璃体腔注射康柏西普治疗视网膜分支静脉阻塞(BRVO)继发黄斑水肿(ME)的临床疗效。

方法：回顾性分析。选取2016-03/2018-05经本院诊治的BRVO继发ME患者86例86眼，根据治疗方式不同分对照组患者43例43眼给予玻璃体腔注射雷珠单抗治疗，研究组患者43例43眼给予玻璃体腔注射康柏西普治疗。随访6mo，比较两组患者治疗前、治疗后1、3、6mo的黄斑中心区厚度(CMT)和最佳矫正视力(BCVA)，记录随访期间两组患者的注射次数及并发症发生情况。

结果：治疗后1、3、6mo时，研究组患者LogMAR BCVA(0.57±0.29、0.42±0.21、0.38±0.12)和CMT(343.56±46.23、316.68±38.25、283.56±29.47μm)与对照组(LogMAR BCVA：0.58±0.30、0.43±0.23、0.40±0.13； CMT：345.47±46.53、317.83±38.46、284.34±29.56μm)比较无差异(P>0.05)； 研究组患者平均注射次数(2.25±1.16次)明显低于对照组\〖(4.37±1.58)次，P<0.05\〗； 治疗期间两组患者均未出现持续性高眼压、眼内炎、视网膜脱落、玻璃体出血等并发症。

结论：玻璃体腔注射康柏西普治疗BRVO继发ME的疗效显著，安全性好，可明显减少注射次数。

METHODS: From March 2016 to May 2018, 86 patients(86 eyes)with BRVO secondary macular edema were selected. 43 patients(43 eyes)were divided into the study group and the control group. Patients in the control group were treated with intravitreal injection of razumab, while patients in the study group were treated with intravitreal injection of conbercept. The patients were followed up for 6mo. The central macular thickness(CMT)and best corrected visual acuity(BCVA)were compared before treatment(T0), 1mo after treatment(T1), 3mo after treatment(T2), 6mo after treatment(T3). The number of injections and complications were recorded during the follow-up period.

RESULTS: At 1mo, 3mo and 6mo after treatment, the levels of LogMAR BCVA(0.57±0.29, 0.42±0.21, 0.38±0.12)and CMT(343.56±46.23, 316.68±38.25, 283.56±29.47μm)in the study group were compared with those in the control group(BCVA: 0.58±0.30, 0.43±0.23, 0.40±0.13). The comparison of CMT: 345.47±46.53, 317.83±38.46, 284.34±29.56μm showed no statistical difference(PSymbol～@@0.05); the average number of injections in the study group was(2.25±1.16)times, which was significantly lower than that in the control group \〖(4.37±1.58)times, P<0.05\〗; There was no persistent ocular hypertension, endophthalmitis, retinal detachment, vitreous hemorrhage and other complications in both groups.

CONCLUSION: Vitreous injection of conbercept is effective and safe in the treatment of ME secondary to BRVO, and can significantly reduce the number of injections.